Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
The beneficial treatment with several statins have been eval
2024-05-17
The beneficial treatment with several statins have been evaluated in AD patients (Kivipelto et al., 2005), with controversial results. It has been suggested that statins slow cognitive decline in mild to moderate AD (Miida et al., 2005). Treatment with atorvastatin, combined with other medications,
-
agonists simulate norepinephrine NE in binding to
2024-05-17
α2 agonists simulate norepinephrine (NE) in binding to presynaptic surface autoreceptors, which in turn mediates feedback inhibition of NE release. Another major control mechanism for noradrenergic neurotransmission is termination of signaling by presynaptic NE transporter (NET)-mediated NE reuptake
-
The specific binding domain between PGK in group
2024-05-17
The specific binding domain between PGK in group B strepotocci (GBS) and actin had been reported . PGK as the actin-binding protein identified in TMW 1.1434, which displayed highly significant adhesion was investigated for the binding sites and compared to bacteria with less strong adhesion to actin
-
Changes in actin microfilaments are mediated
2024-05-17
Changes in Go 6983 microfilaments are mediated by changes in extracellular matrix, mechanical stimulation or growth factors intracellular signaling. We observed significant changes in a number of intracellular signaling pathways associated with changes in actin dynamics during hMSCs differentiation
-
Taken together BRP represents a novel chemotype of
2024-05-17
Taken together, BRP-187 represents a novel chemotype of LT biosynthesis inhibitors with outstanding potency in human PMNL and monocytes activated under pathophysiological relevant conditions and with effectiveness in vivo. Using the PLA that visualizes the in situ interaction between 5-LO and FLAP i
-
hydroxydopamine OHDA is a selective catecholaminergic
2024-05-17
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and
-
GW-1100 receptor br Conflict of interest br Acknowledgements
2024-05-17
Conflict of interest Acknowledgements We thank Ann Jackman, Mike Ormerod and members of Julian Downward's and Alan Ashworth's groups for helpful discussions. This work was supported by grant number PEM/GME/D391/40 from the Kidani Trust (S. Kaye) and by Keele University. Introduction Autota
-
PF also a dual Aurora A and Aurora B inhibitor
2024-05-16
PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly VUF 11207 fumarate sale for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the
-
br Introduction Lipoxygenases LOXs are a heterogeneous
2024-05-16
Introduction Lipoxygenases (LOXs) are a heterogeneous family of enzymes that catalyze the peroxidation of polyunsaturated fatty acids (PUFAs). By oxidizing free PUFAs, they were shown to contribute to the generation of various bioactive lipid mediators. However, LOX-mediated oxidation of PUFAs es
-
br Transparency document br Acknowledgments
2024-05-16
Transparency document Acknowledgments This work has been supported by the National Eye Institute (NIH) Grant 5R01EY023315-02 (MA). This study was also supported in part by National Center for Research Resources Grant S10RR027926 for the lipid analysis and by James and Jean Culver Vision Discov
-
Based on the extracellular domain structures we
2024-05-16
Based on the extracellular domain structures, we can infer that the dimer arrangement of GABAB receptor will undergo substantial changes upon receptor activation (Geng et al., 2013). First, agonist-stimulated closure of GABAB1 VFT would cause an upward rotation of its LB2 domain, coupled with an inw
-
Most of lipid lowering agents have many
2024-05-16
Most of lipid-lowering agents have many therapeutic problems with severe side effects, while dietary fibers as lipid lowering therapy are safer. Chitosan (CS) is a dietary fiber biodegradable, biocompatible and has many health benefits including wound healing, antiinflammatory, anti-cancers, immune-
-
To better illustrate the involved neuronal postganglionic
2024-05-16
To better illustrate the involved neuronal postganglionic pathways, central apelin-13 injection was performed in rats received peripheral preadministration of NOS inhibitor L-NAME, sympatholytic agent guanethidine and/or muscarinic receptor agonist bethanechol. Compared with the rats received vehicl
-
Apelin is a peptide hormone and an endogenous ligand
2024-05-16
Apelin is a peptide hormone and an endogenous ligand for a G protein-coupled receptor named APJ [7], [8], and apelin and APJ are widely expressed in human organs including hypothalamus, heart, lungs, kidneys, adipose tissue, muscles, and others [9]. Apelin is initially synthesized as a 77-amino-acid
-
Anti angiogenic activity of natural products in ocular neova
2024-05-16
Anti-angiogenic activity of natural products in ocular neovascularization A number of molecules, obtained from the natural source, have been evaluated for ocular neovascularization [14], [15]. As these compounds exhibit antioxidant effects, these were also tried for their therapeutic efficacy in in
15646 records 123/1044 page Previous Next First page 上5页 121122123124125 下5页 Last page